Comparison of CYP3A activities in a subclone of Caco-2 cells (TC7) and human intestine

Pharmaceutical Research

Volumn 14, Issue 8, 1997, Pages 1019-1025

  Raeissi, Shamsi D ^a,b   Guo, Zuyu ^a   Dobson, Glenn L ^a   Artursson, Per ^b   Hidalgo, Ismael J ^a,c  

^a SANOFI   (France)

^b UPPSALA UNIVERSITY   (Sweden)

^c Absorption Systems   (United States)

Author keywords

Caco 2; CYP3A; Intestinal metabolism; TC7; Terfenadine

Indexed keywords

CYTOCHROME C OXIDASE; CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; KETOCONAZOLE; TERFENADINE; TROLEANDOMYCIN;

ARTICLE; CELL STRAIN CACO 2; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE EPITHELIUM CELL; LIVER MICROSOME; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL;

ANTIBODIES; ARYL HYDROCARBON HYDROXYLASES; CACO-2 CELLS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; HYDROXYLATION; INTESTINAL MUCOSA; JEJUNUM; KETOCONAZOLE; MICROSOMES; MICROSOMES, LIVER; OXIDATION-REDUCTION; OXIDOREDUCTASES, N-DEMETHYLATING; STEROID HYDROXYLASES; TERFENADINE; TROLEANDOMYCIN;

EID: 0030828439     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012197110917     Document Type: Article

References (21)

1. J. C. Kolars, W. M. Awni, R. M. Merion, and P. B. Watkins. The Lancet 338:1488-1490 (1991).
2. W. A. Mahon, T. Inaba, and R. M. Stone. Clin. Pharmacol Ther. 22:228-233 (1977).
3. L. S. Kaminsky and M. J. Fasco. Toxicology 21:407-422 (1992).
4. J. C. Kolars, P. Schmiedlin-Ren, J. D. Schuetz, C. Fang, and P. B. Watkins. J. Clin. Invest. 90:1871-1878 (1992).
5. P. B. Watkins, S. A. Wrighton, E. G. Schuetz, D. T. Molowa, and P. S. Guzelian. J. Clin. Invest. 80:1029-1036 (1987).
6. L. Gervot, V. Carriere, P. Costet, P. Cugenenc, A. Berger, P. H. Beaune, and I. de Waziers. Env. Toxicol. Pharmacol. 2:381-388 (1996).
7. I. J. Hidalgo, T. J. Raub, and R. T. Borchardt. Gastroenterology 96:736-49 (1989).
8. K. L. Audus, R. L. Bartel, I. J. Hidalgo, and R. T. Borchardt. Pharm. Res. 7:435-451 (1990).
9. P. Artursson. Crit. Rev. Ther. Drug Carrier System 8:305-330 (1991).
10. A. Baranczyk-Kuzma, J. A. Garren, I. J. Hidalgo, and R. T. Borchardt. Life Sci. 49:1197-1206 (1991).
11. W. H. M. Peters and H. M. J. Roelofs. Cancer Res. 52:1886-1890 (1992).
12. X. Boulenc, M. Bourrie, I. Fabre, C. Roque, H. Joyeux, Y. Berger, and G. J. Fabre. J. Pharmacol Exper. Ther. 263:1471-1478 (1992).
13. V. Carriere, T. Lesuffleur, A. Barbat, M. Rousset, E. Dussaulx, P. Costet, I. Wazier, P. Beasune, and A. Zweibaum. FEBS Lett. 355:247-250 (1994).
14. C.-H. Yun, R. A. Okerholm, and F. P. Guengerich. Drug Metab. Disp. 21:403-409 (1993).
15. M. Jurima-Romet, K. Crawford, T. Cyr, and T. Inaba. 22:849-857 (1994).
16. A. D. Rodrigues, D. J. Mulford, R. D. Lee, B. W. Surber, M. J. Kukuka, J. L. Ferrero, S. B. Thomas, M. S. Shet, and R. W. Estabrook. Drug Metabo. Disp. 23:765-409 (1995).
17. K.-H Ling, G. A. Leeson, S. D. Burmaster, R. H. Hook, M. K. Reith, and L. K. Cheng. Drug Metab. Disp. 23:631-636 (1995).
18. T. Aoyama, S. Yamano, D. J. Waxman, D. P. Lapenson, U. A. Meyer, V. Fischer, R. Tyndale, T. Inaba, W. Kalow, H. V. Gelboin, and F. J. Gonzalez. J. Biol. Chem. 264:97-105 (1989).
19. S. A. Wrighton, B. J. Ring, P. B. Watkins, and M. VandenBranden. Mol. Pharmacol. 38:3147-3155 (1989).
20. S. A. Wrighton, W. R. Brian, M-A. Sari, M. Iwasaki, F. P. Guengerich, J. L. Raucy, D. T. Malowa, and M. VandenBranden. Mol. Pharmacol. 38:207-213 (1990).
21. J. C. Gorski, S. D. Hall, D. R. Jones, M. VandenBranden, and S. A. Wrighton. Biochem. Pharmacol. 47:1643-1653 (1994).